No Data
No Data
Xuantai Pharmaceutical (688247.SH): has repurchased 0.96% of the shares accumulated.
Announced by Xiantai Medicine (688247.SH) on October 8th, as of September 30, 2024, the company has repurchased a total of 4,336,109 shares through the Shanghai Stock Exchange trading system via centralized bidding trading, accounting for 0.96% of the total share capital of 453,340,000 shares. The highest purchase price was 8.98 yuan per share, the lowest price was 7.40 yuan per share, and the total amount paid was RMB 36,126,025.26 (excluding stamp duty, transaction commission, and other transaction costs).
Sinotherapeutics Inc.'s (SHSE:688247) Biggest Owners Are Private Equity Firms Who Got Richer After Stock Soared 12% Last Week
Sinotherapeutics Gets China Nod for Type 2 Diabetes Sustained-Release Tablets
Xuantai Pharmaceutical (688247.SH): The product Dapagliflozin Metformin SR Tablets has obtained the pharmaceutical registration certificate.
On September 18, GeLongHui announced that XuanTai Pharmaceutical (688247.SH) has received official approval for its generic version of Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets, making it the first domestically approved generic pharmaceutical for this type of medication in China. The approved Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets, used to treat type 2 diabetes, were developed by AstraZeneca and were launched in China in June 2023. They are included in the National Medical Insurance Category B for reimbursement.
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
No Data
No Data